Primary Myelofibrosis clinical trials at UCSF
2 research studies open to eligible people
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
open to eligible people ages 18 years and up
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question[s] it aims to answer are: - Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? - Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose of PTCy?
San Francisco 5391959, California 5332921 and other locations
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
open to all eligible people
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
San Francisco 5391959, California 5332921 and other locations
Our lead scientists for Primary Myelofibrosis research studies include Aaron Logan, MD.
Last updated: